- Needham analyst Alex Henderson hosted a Networking and Security oriented expert call with Joe Hlavin of n2grate Technology Solutions, a data center and cloud integration firm focusing on hardware, software, and cloud services for large Enterprises and the Federal sector.
- Henderson’s discussion focused on C-Suites’ handling of the broader macro environment, budget shifts and re-prioritization, lead times, and pricing dynamics.
- Budgets for CY23 were assumed flat, but businesses prioritized data center/security and shifting to software, noted Henderson.
- Lead times remained long, with firms struggling to predict supply.
- Software replaced hardware where possible, especially in Federal mandating physical delivery of the product to count toward current budgets.
- Pricing increases have not fully taken hold, but sales slowly added strings to significant discounts.
- The call fetched positive comments from VAR for Zscaler, Inc (NASDAQ:ZS) ($159.93, Strong Buy Rated, Price Target $185):, Okta, Inc (NASDAQ:OKTA) ($101.95, Buy Rated, Price Target $135):, Palo Alto Networks, Inc (NASDAQ:PANW), Fortinet, Inc (NASDAQ:FTNT), SentinelOne, Inc (NYSE:S) ($25.26, Buy Rated, Price Target $31):, and CrowdStrike Holdings, Inc (NASDAQ:CRWD) ($183.53, Buy Rated, Price Target $210).
- It saw Neutral comments on Arista Networks, Inc (NYSE:ANET) ($102.38, Buy Rated, Price Target $128) and Cisco Systems, Inc (NASDAQ:CSCO) ($44.46, Hold Rated).
- It also saw a modestly negative view of Juniper Networks, Inc (NYSE:JNPR) ($28.61, Buy Rated, Price Target $38).
Needham Sees Comm & Enterprise Infra Budgets Intact; Priorities Shifting to Security and Cloud
Needham analyst Alex Henderson hosted a Networking and Security oriented expert call with Joe Hlavin of n2grate Technology Solutions, a data center and cloud integration firm focusing on hardware, software, and cloud services for large Enterprises and the Federal sector.
Related Posts
Novartis Announced Earlier, Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful And Highly Statistically Significant Proteinuria Reduction In Patients With IGA Nephropathy; Phase III ALIGN Study Met Its Primary Endpoint
Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgA
China’s Policymakers Plan To Step Up Support For Domestic Demand This Year With Focus On Investment Vs Stimulus
-Reuters
https://www.reuters.com/markets/asia/big-stimulus-unlikely-china-considers-steps-support-consumers-sources-2023-02-03/
BMO Capital Maintains Outperform on Stingray Group, Raises Price Target to C$8
BMO Capital analyst Tim Casey maintains Stingray Group (TSX:RAY) with a Outperform and raises the price target from C$6.5 to C$8.